Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luprostiol is a synthetic analogue of prostaglandin F2α, classified as a luteolytic agent. Its primary mechanism of action is to induce luteal regression in animals with an active corpus luteum, leading to subsequent follicle growth, estrus, and ovulation. It is used primarily in veterinary medicine for estrus control and termination of pregnancy in mares and cattle. Luprostiol acts by mimicking the effects of endogenous prostaglandin F2α on the corpus luteum, resulting in its breakdown (luteolysis). The drug is rapidly absorbed after intramuscular injection and metabolized quickly. It has been formulated as an injectable solution (typically 7.5 mg/mL) and has been available for veterinary use in Europe for several years[3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on luprostiol.